Jon Cousin - Partner // Cooley // Global Law Firm (2024)

Div Gupta

Partner, New York

Christina T. Roupas

Partner in Charge – Chicago, Chicago

Courtney M.W. Tygesson

Partner, Chicago

Laurie Bauer

Partner, Chicago

Nyron J. Persaud

Partner, New York

Kate Hillier

Partner, Seattle

Jon Cousin

Partner, Washington, DC

Elizabeth Anne Wright

Of Counsel, Brussels

Eileen Marshall

Partner, Washington, DC

Geoffrey Spolyar

Partner, Boston

Stephanie Gentile

Partner, New York

Steve Flores

Partner, Chicago

Peter Adams

Partner, San Diego

Phil Mitchell

Partner, New York

Courtney Thorne

Partner, Boston

David Navetta

Partner, Colorado

Francis Wheeler

Partner, Colorado

Natasha Leskovsek

Of Counsel, Washington, DC

Jennifer Shanley

Special Counsel, New York

Rebecca Ross

Special Counsel, Washington, DC

Randy Sabett

Special Counsel, Washington, DC

Dani Nazemian

Special Counsel, San Diego

Katie Lapidus

Associate, Washington, DC

Trey Reilly

Associate, New York

Adam Bloom

Associate, Chicago

David D. Suh

Associate, Palo Alto

Dionne A. Thomas

Associate, San Diego

Megan E. Bowles

Associate, Chicago

Mor Agam

Associate, New York

Nat Sherrick

Associate, Washington, DC

Edmond Lay

Associate, San Diego

Addison Pierce

Associate, Chicago

Calvin Lee

Associate, New York

Andrew Nelms

Associate, San Francisco

Jason Minio

Paralegal Specialist, Boston

Jeffery Wyzykowski

Patent Agent, Washington, DC

Capital Markets

Life Sciences

Life Sciences and Healthcare Regulatory

Life Sciences Corporate Partnering and Licensing

Healthcare

Patent Counseling and Prosecution

Emerging Companies

Public Companies

Compensation and Benefits

Labor and Employment

Cyber/Data/Privacy

Debt Finance

CFIUS

Tax

Mischi a Marca

Partner, San Francisco

Michael Tollini

Partner, Washington, DC

Addison Pierce

Associate, Chicago

Matt Kong

Associate, San Francisco

Ivor Elrifi

Partner, New York

Xander Lee

Partner, Los Angeles Santa Monica

Geoffrey Spolyar

Partner, Boston

Jon Cousin

Partner, Washington, DC

Steve Flores

Partner, Chicago

Phil Mitchell

Partner, New York

Michael Egan

Partner, Washington, DC

Jeffrey J. Tolin

Partner, New York

Michael Klein

Partner, New York

Natasha Leskovsek

Of Counsel, Washington, DC

Robert Eisenbach

Of Counsel, San Francisco

Susan Piascik Christoff

Special Counsel, Washington, DC

Karen Tsai

Special Counsel, Washington, DC

Cathy Hershcopf

Senior Counsel, New York

Stevie Yu

Associate, New York

Yichao Zhang

Associate, New York

Rodrigo Huerta

Associate, Chicago

Jackson Alldredge

Associate, Colorado

Amanda Pacheco

Associate, Palo Alto

Celine Koh

Associate, Palo Alto

Jameson Davis

Associate, Boston

Allison Kutner

Associate, New York

Matthew S. Scarano

Associate, San Diego

Xueqing Li

Associate, San Francisco

Mor Agam

Associate, New York

Miriam Peguero Medrano

Associate, Chicago

Sam Rabuck

Associate, Chicago

Chris Rhem

Paralegal Specialist, San Francisco

Veronica Cortes

Paralegal Specialist, New York

Jennifer Fitzpatrick

Paralegal Specialist, Washington, DC

Jason Minio

Paralegal Specialist, Boston

Jeffery Wyzykowski

Patent Agent, Washington, DC

Debt Finance

Life Sciences

Life Sciences Corporate Partnering and Licensing

Patent Counseling and Prosecution

Trademark, Copyright and Advertising

Tax

Cyber/Data/Privacy

Compensation and Benefits

Healthcare

Business Restructuring

Laurie Bauer

Partner, Chicago

Edmond Lay

Associate, San Diego

Megan E. Bowles

Associate, Chicago

Adam Bloom

Associate, Chicago

Kate Hillier

Partner, Seattle

David D. Suh

Associate, Palo Alto

Jon Cousin

Partner, Washington, DC

Andrew Epstein

Special Counsel, Seattle

Annie Froehlich

Partner, Washington, DC

Steve Flores

Partner, Chicago

Dionne A. Thomas

Associate, San Diego

Jodie Bourdet

Partner, San Francisco

Emerging Companies

Venture Capital

Healthcare

Life Sciences

Cooley advised Secura Bio on intellectual property diligence matters surrounding its acquisition of global rights to Farydak from Novartis. Farydak is a prescription medication used to treat patients who have received prior treatment for multiple myeloma, a cancer that forms malignant plasma cells in the bone marrow.

“We are very pleased to acquire worldwide rights to Farydakas we execute our plan to aggressively build a meaningful, worldwide oncology portfolio,” saidJoseph M. Limber, president and CEO at Secura Bio. “Farydak will be a critical cornerstone of our strategy, as it offers a potentially valuable and high-growth treatment option for physicians in their therapeutic regimen for multiple myeloma patients when combined with a variety of other multiple myeloma therapies.”

Jon Cousin

Partner, Washington, DC

Intellectual Property

Patent Counseling and Prosecution

Patent Counseling and Prosecution – Life Sciences

Cooley advised Secura Bio on intellectual property diligence matters surrounding its $311 million acquisition ($70 million upfront and $241 million in milestones) of global rights to Copiktra. Copiktra is a prescription oncology medication used to treat patients who have received prior treatment for certain types of cancer, such as chronic lymphocytic leukemia and small lymphocytic lymphoma.

“Completing the Copiktra acquisition represents a major step in building our worldwide oncology portfolio,” saidJoseph M. Limber, president and CEO at Secura Bio.

Jon Cousin

Partner, Washington, DC

Intellectual Property

Patent Counseling and Prosecution

Patent Counseling and Prosecution – Life Sciences